[go: up one dir, main page]

ATE375164T1 - Endotoxin-bindung durch milchsäurebakterien und bifidobacteria - Google Patents

Endotoxin-bindung durch milchsäurebakterien und bifidobacteria

Info

Publication number
ATE375164T1
ATE375164T1 AT02719762T AT02719762T ATE375164T1 AT E375164 T1 ATE375164 T1 AT E375164T1 AT 02719762 T AT02719762 T AT 02719762T AT 02719762 T AT02719762 T AT 02719762T AT E375164 T1 ATE375164 T1 AT E375164T1
Authority
AT
Austria
Prior art keywords
bifidobacteria
lactic acid
acid bacteria
endotoxin binding
endotoxin
Prior art date
Application number
AT02719762T
Other languages
English (en)
Inventor
Eduardo Schiffrin
Guillermo Kociubinski
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8179863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE375164(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Application granted granted Critical
Publication of ATE375164T1 publication Critical patent/ATE375164T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
AT02719762T 2001-02-06 2002-02-01 Endotoxin-bindung durch milchsäurebakterien und bifidobacteria ATE375164T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01200436 2001-02-06

Publications (1)

Publication Number Publication Date
ATE375164T1 true ATE375164T1 (de) 2007-10-15

Family

ID=8179863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719762T ATE375164T1 (de) 2001-02-06 2002-02-01 Endotoxin-bindung durch milchsäurebakterien und bifidobacteria

Country Status (21)

Country Link
US (2) US7550285B2 (de)
EP (1) EP1359924B1 (de)
JP (3) JP2004531477A (de)
KR (1) KR100845456B1 (de)
CN (1) CN1250232C (de)
AT (1) ATE375164T1 (de)
AU (1) AU2002250886B2 (de)
BR (1) BR0207019A (de)
CA (1) CA2436264C (de)
DE (1) DE60222856T2 (de)
EA (1) EA006397B1 (de)
ES (1) ES2292744T3 (de)
HK (1) HK1066174A1 (de)
IL (1) IL157071A0 (de)
MX (1) MXPA03007024A (de)
NO (1) NO20033372D0 (de)
NZ (1) NZ527493A (de)
PL (1) PL367083A1 (de)
PT (1) PT1359924E (de)
WO (1) WO2002062360A1 (de)
ZA (1) ZA200306935B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207019A (pt) * 2001-02-06 2004-02-25 Nestle Sa Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
EP1885383B1 (de) 2005-05-31 2016-09-21 IAMS Europe B.V. Katzen probiotisches bifidobacterium
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
US20090083067A1 (en) * 2006-03-29 2009-03-26 Mary Elaine Freeland Methods and kits for selecting a health care product
ES2551719T3 (es) 2007-02-01 2015-11-23 Iams Europe B.V. Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
MX2009009119A (es) * 2007-02-28 2009-09-04 Mead Johnson Nutrition Co Metodo para tratar o prevenir la inflamacion sistemica.
KR100913406B1 (ko) * 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
ES2708450T3 (es) 2009-07-30 2019-04-09 Dupont Nutrition Biosci Aps Bacterias ácido lácticas y bifidobacterias para tratar endotoxemia
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011069860A1 (en) 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
JP2010280664A (ja) * 2010-07-02 2010-12-16 Biogaia Ab ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法
US20140234487A1 (en) 2011-07-13 2014-08-21 Friesland Brands B.V. Dairy based compositions with low lps
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
KR102001721B1 (ko) * 2013-09-30 2019-07-18 이엘씨 매니지먼트 엘엘씨 워터리 로션 피부 관리 조성물 및 방법
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
CN104498375B (zh) * 2014-12-02 2017-05-10 江南大学 一株具有内毒素吸附特性的耶氏酵母及其吸附特性研究方法
JP6710075B2 (ja) * 2016-03-29 2020-06-17 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
TWI640319B (zh) * 2017-05-12 2018-11-11 健茂生物科技股份有限公司 具有抗發炎活性之醱酵液的製備方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP6888145B2 (ja) * 2020-03-23 2021-06-16 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
WO2021253017A2 (en) * 2020-06-07 2021-12-16 Ramasamy Sundaram Compositions and methods for detoxifying bacterial endotoxins and hydrogen sulfide by recombinant fusion enzymes
WO2022043223A1 (en) 2020-08-28 2022-03-03 Chr. Hansen A/S Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555618A (en) * 1896-03-03 Hay-loader
IT1254210B (it) * 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
JP2506314B2 (ja) * 1993-10-27 1996-06-12 全国農業協同組合連合会 家禽・豚の敗血症の予防・治療剤及び飼料
US6506389B2 (en) * 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
PT862863E (pt) * 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
NZ512275A (en) * 1998-12-11 2003-11-28 Urex Biotech Inc Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens
HUP0301059A3 (en) * 2000-03-24 2004-10-28 Nestle Sa Use of lactic acid bacterium for the treatment of peritonitis
BR0207019A (pt) * 2001-02-06 2004-02-25 Nestle Sa Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias

Also Published As

Publication number Publication date
HK1066174A1 (en) 2005-03-18
NO20033372L (no) 2003-07-28
NO20033372D0 (no) 2003-07-28
EA200300862A1 (ru) 2003-12-25
EP1359924A1 (de) 2003-11-12
JP2011246483A (ja) 2011-12-08
DE60222856T2 (de) 2008-07-24
EP1359924B1 (de) 2007-10-10
PT1359924E (pt) 2007-12-07
US20100136662A1 (en) 2010-06-03
WO2002062360A1 (en) 2002-08-15
CN1501805A (zh) 2004-06-02
US7964384B2 (en) 2011-06-21
JP2004531477A (ja) 2004-10-14
NZ527493A (en) 2005-06-24
MXPA03007024A (es) 2003-11-18
JP5973701B2 (ja) 2016-08-23
KR20030076652A (ko) 2003-09-26
AU2002250886B2 (en) 2007-08-02
ZA200306935B (en) 2004-12-06
CA2436264A1 (en) 2002-08-15
CN1250232C (zh) 2006-04-12
JP2014062104A (ja) 2014-04-10
DE60222856D1 (de) 2007-11-22
US7550285B2 (en) 2009-06-23
PL367083A1 (en) 2005-02-21
US20040115178A1 (en) 2004-06-17
IL157071A0 (en) 2004-02-08
ES2292744T3 (es) 2008-03-16
EA006397B1 (ru) 2005-12-29
KR100845456B1 (ko) 2008-07-10
BR0207019A (pt) 2004-02-25
CA2436264C (en) 2014-01-28

Similar Documents

Publication Publication Date Title
ATE375164T1 (de) Endotoxin-bindung durch milchsäurebakterien und bifidobacteria
EP2341063A3 (de) Neue immunogene Zusammensetzungen zur Prävention und Behandlung der Meningokokken-Erkrankung
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
IL147271A0 (en) Compounds that bind her2
EP2305640A3 (de) Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008148873A3 (en) Hydroxyproline compositions and uses thereof
WO2005110445A3 (en) Methods and compositions for the dietary management of autoimmune disorders
MX2009012011A (es) Composiciones aireadas y liofilizadas lacteas o de sustituto lacteo, y metodos para su elaboracion.
SI2076271T1 (sl) Inhibicija toksinov kolere z galatooligosaharidi (GOS)
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006082328A3 (fr) Compositions comprenant des micro-organismes deshydrates, leurs procedes de preparation, et leurs utilisations
BR0214902A (pt) Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
WO2007140011A3 (en) Erythroid progenitor cells and methods for producing parvovirus b19 therein
WO2006034001A3 (en) Methods of treating hiv infection
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
WO2006129092A3 (en) Use of bacteriophage in medicaments
DE60235418D1 (de) Osteoprotegerin in Milch
WO2006046871A3 (en) Peri-operative composition comprising lactobacillus rhamnosus
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
WO2003026693A3 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
WO2009057282A1 (ja) 骨吸収抑制用食品素材
HK1084023A1 (en) Glycosaminoglycans for treating emotional dysfunctions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties